Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 97 to 100 of 100 entries
Sorted by: Best Match Show Resources per page
Epstein-Barr Virus in Salivary Samples from Systemic Lupus Erythematosus Patients with Oral Lesions.

Journal of clinical medicine

Buonavoglia A, Leone P, Prete M, Solimando AG, Guastadisegno C, Lanave G, Camero M, Martella V, Lo Muzio L, Racanelli V.
PMID: 34768514
J Clin Med. 2021 Oct 27;10(21). doi: 10.3390/jcm10214995.

In order to investigate the possible role of Epstein-Barr virus (EBV) in systemic lupus erythematosus (SLE) and its associated oral lesions, a pilot case-control study was performed. A total of 31 patients (18 females and 13 males) were enrolled...

Cite
Buonavoglia A, Leone P, Prete M, et al. Epstein-Barr Virus in Salivary Samples from Systemic Lupus Erythematosus Patients with Oral Lesions. J Clin Med. 2021;10(21)doi: 10.3390/jcm10214995.
Buonavoglia, A., Leone, P., Prete, M., Solimando, A. G., Guastadisegno, C., Lanave, G., Camero, M., Martella, V., Lo Muzio, L., & Racanelli, V. (2021). Epstein-Barr Virus in Salivary Samples from Systemic Lupus Erythematosus Patients with Oral Lesions. Journal of clinical medicine, 10(21), . https://doi.org/10.3390/jcm10214995
Buonavoglia, Alessio, et al. "Epstein-Barr Virus in Salivary Samples from Systemic Lupus Erythematosus Patients with Oral Lesions." Journal of clinical medicine vol. 10,21 (2021). doi: https://doi.org/10.3390/jcm10214995
Buonavoglia A, Leone P, Prete M, Solimando AG, Guastadisegno C, Lanave G, Camero M, Martella V, Lo Muzio L, Racanelli V. Epstein-Barr Virus in Salivary Samples from Systemic Lupus Erythematosus Patients with Oral Lesions. J Clin Med. 2021 Oct 27;10(21). doi: 10.3390/jcm10214995. PMID: 34768514; PMCID: PMC8584540.
Copy Download .nbib Format: NLM
Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs.

Journal of personalized medicine

Derakhshani A, Asadzadeh Z, Safarpour H, Leone P, Shadbad MA, Heydari A, Baradaran B, Racanelli V.
PMID: 34442365
J Pers Med. 2021 Jul 27;11(8). doi: 10.3390/jpm11080721.

Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS) that is characterized by inflammation which typically results in significant impairment in most patients. Immune checkpoints act as co-stimulatory and co-inhibitory molecules and play a...

Cite
Derakhshani A, Asadzadeh Z, Safarpour H, et al. Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs. J Pers Med. 2021;11(8)doi: 10.3390/jpm11080721.
Derakhshani, A., Asadzadeh, Z., Safarpour, H., Leone, P., Shadbad, M. A., Heydari, A., Baradaran, B., & Racanelli, V. (2021). Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs. Journal of personalized medicine, 11(8), . https://doi.org/10.3390/jpm11080721
Derakhshani, Afshin, et al. "Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs." Journal of personalized medicine vol. 11,8 (2021). doi: https://doi.org/10.3390/jpm11080721
Derakhshani A, Asadzadeh Z, Safarpour H, Leone P, Shadbad MA, Heydari A, Baradaran B, Racanelli V. Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate Drugs. J Pers Med. 2021 Jul 27;11(8). doi: 10.3390/jpm11080721. PMID: 34442365; PMCID: PMC8400811.
Copy Download .nbib Format: NLM
Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection.

Journal of clinical medicine

Karami H, Derakhshani A, Ghasemigol M, Fereidouni M, Miri-Moghaddam E, Baradaran B, Tabrizi NJ, Najafi S, Solimando AG, Marsh LM, Silvestris N, De Summa S, Paradiso AV, Racanelli V, Safarpour H.
PMID: 34441862
J Clin Med. 2021 Aug 13;10(16). doi: 10.3390/jcm10163567.

The coronavirus disease-2019 (COVID-19) pandemic has caused an enormous loss of lives. Various clinical trials of vaccines and drugs are being conducted worldwide; nevertheless, as of today, no effective drug exists for COVID-19. The identification of key genes and...

Cite
Karami H, Derakhshani A, Ghasemigol M, et al. Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection. J Clin Med. 2021;10(16)doi: 10.3390/jcm10163567.
Karami, H., Derakhshani, A., Ghasemigol, M., Fereidouni, M., Miri-Moghaddam, E., Baradaran, B., Tabrizi, N. J., Najafi, S., Solimando, A. G., Marsh, L. M., Silvestris, N., De Summa, S., Paradiso, A. V., Racanelli, V., & Safarpour, H. (2021). Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection. Journal of clinical medicine, 10(16), . https://doi.org/10.3390/jcm10163567
Karami, Hassan, et al. "Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection." Journal of clinical medicine vol. 10,16 (2021). doi: https://doi.org/10.3390/jcm10163567
Karami H, Derakhshani A, Ghasemigol M, Fereidouni M, Miri-Moghaddam E, Baradaran B, Tabrizi NJ, Najafi S, Solimando AG, Marsh LM, Silvestris N, De Summa S, Paradiso AV, Racanelli V, Safarpour H. Weighted Gene Co-Expression Network Analysis Combined with Machine Learning Validation to Identify Key Modules and Hub Genes Associated with SARS-CoV-2 Infection. J Clin Med. 2021 Aug 13;10(16). doi: 10.3390/jcm10163567. PMID: 34441862; PMCID: PMC8397209.
Copy Download .nbib Format: NLM
CT pulmonary angiography appropriateness in a single emergency department: does the use of revised Geneva score matter?.

La Radiologia medica

Mirabile A, Lucarelli NM, Sollazzo EP, Stabile Ianora AA, Sardaro A, Mirabile G, Lorusso F, Racanelli V, Maggialetti N, Scardapane A.
PMID: 34518985
Radiol Med. 2021 Sep 13; doi: 10.1007/s11547-021-01416-x. Epub 2021 Sep 13.

PURPOSE: To assess the percentage of computed tomography pulmonary angiography (CTPA) procedures that could have been avoided by methodical application of the Revised Geneva Score (RGS) coupled with age-adjusted D-dimer cut-offs rather than only clinical judgment in Emergency Department...

Cite
Mirabile A, Lucarelli NM, Sollazzo EP, et al. CT pulmonary angiography appropriateness in a single emergency department: does the use of revised Geneva score matter?. Radiol Med. 2021;doi: 10.1007/s11547-021-01416-x.
Mirabile, A., Lucarelli, N. M., Sollazzo, E. P., Stabile Ianora, A. A., Sardaro, A., Mirabile, G., Lorusso, F., Racanelli, V., Maggialetti, N., & Scardapane, A. (2021). CT pulmonary angiography appropriateness in a single emergency department: does the use of revised Geneva score matter?. La Radiologia medica, . https://doi.org/10.1007/s11547-021-01416-x
Mirabile, Alessandra, et al. "CT pulmonary angiography appropriateness in a single emergency department: does the use of revised Geneva score matter?." La Radiologia medica vol. (2021). doi: https://doi.org/10.1007/s11547-021-01416-x
Mirabile A, Lucarelli NM, Sollazzo EP, Stabile Ianora AA, Sardaro A, Mirabile G, Lorusso F, Racanelli V, Maggialetti N, Scardapane A. CT pulmonary angiography appropriateness in a single emergency department: does the use of revised Geneva score matter?. Radiol Med. 2021 Sep 13; doi: 10.1007/s11547-021-01416-x. Epub 2021 Sep 13. PMID: 34518985.
Copy Download .nbib Format: NLM
Showing 97 to 100 of 100 entries